Cite
A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies.
MLA
Holida, Myrl, et al. “A Phase III, Open-Label Clinical Trial Evaluating Pegunigalsidase Alfa Administered Every 4 Weeks in Adults with Fabry Disease Previously Treated with Other Enzyme Replacement Therapies.” Journal of Inherited Metabolic Disease, Oct. 2024. EBSCOhost, https://doi.org/10.1002/jimd.12795.
APA
Holida, M., Linhart, A., Pisani, A., Longo, N., Eyskens, F., Goker-Alpan, O., Wallace, E., Deegan, P., Tøndel, C., Feldt-Rasmussen, U., Hughes, D., Sakov, A., Rocco, R., Almon, E. B., Alon, S., Chertkoff, R., Warnock, D. G., Waldek, S., Wilcox, W. R., & Bernat, J. A. (2024). A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12795
Chicago
Holida, Myrl, Aleš Linhart, Antonio Pisani, Nicola Longo, François Eyskens, Ozlem Goker-Alpan, Eric Wallace, et al. 2024. “A Phase III, Open-Label Clinical Trial Evaluating Pegunigalsidase Alfa Administered Every 4 Weeks in Adults with Fabry Disease Previously Treated with Other Enzyme Replacement Therapies.” Journal of Inherited Metabolic Disease, October. doi:10.1002/jimd.12795.